Vaccine-Specific Antibody Responses Induced by HIV-1 Envelope Subunit Vaccines

Journal of Immunology

Volumn 158, Issue 7, 1997, Pages 3511-3520

  Pincus, Seth H ^a,b   Messer, Katherine G ^b   Cole, Robert ^b   Ireland, Robin ^b   VanCott, Thomas C ^c   Pinter, Abraham ^d   Schwartz, David H ^e   Graham, Barney S ^f   Gorse, Geoffrey J ^g  

^a MONTANA STATE UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT VACCINE; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANIMAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ARTICLE; CERCOPITHECUS; CHO CELL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HAMSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VERO CELL;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CERCOPITHECUS AETHIOPS; CHO CELLS; CRICETINAE; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNE SERA; MOLECULAR SEQUENCE DATA; VACCINES, SYNTHETIC; VERO CELLS;

EID: 0031112509     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Graham, B. S., R. B. Belshe, M. L. Clements, R. Dolin, L. Corey, P. F. Wright, G. J. Gorse, K. Midthun, M. C. Keefer, N. J. Roberts, Jr., D. H. Schwartz, J. M. Agosti, B. F. Fernie, D. M. Stablein, and D. C. Montefiori. 1992. Vaccination of vaccinia-naive adults with HIV-1 gp160 recombinant vaccinia (HIVAC-1e) in a blinded, controlled, randomized clinical trial. J. Infect. Dis. 166:244.
2. Graham, B. S., T. J. Matthews, R. B. Belshe, M. L. Clements, R. Dolin, P. F. Wright, G. J. Gorse, D. H. Schwartz, M. C. Keefer, D. P. Bolognesi, L. Corey, D. M. Stablein, J. R. Esterlitz, S.-L. Hu, and G. E. Smith. 1993. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J. Infect. Dis. 167:533.
3. Keefer, M. C., B. S. Graham, R. B. Belshe, D. Schwartz, L. Corey, D. P. Bolognesi, D. M. Stablein, D. C. Montefiori, M. J. McElrath, M. L. Clements, G. J. Gorse, P. F. Wright, T. J. Matthews, G. E. Smith, and D. Lawrence. 1994. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. AIDS Res. Hum. Retroviruses 10:1713.
4. Belshe, R. B., M. L. Clements, R. Dolin, B. S. Graham, J. McElrath, G. J. Gorse, D. Schwartz, M. C. Keefer, P. Wright, L. Corey, D. P. Bolognesi, T. J. Matthews, D. M. Stablein, F. S. O'Brien, and M. Eibl. 1993. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J. Infect. Dis. 168:1387.
5. Schwartz, D. H., G. Gorse, M. L. Clements, R. Belshe, A. Izu, A.-M. Duliege, P. Berman, T. Twadell, D. Stablein, R. Sposto, R. Siliciano, and T. Matthews. 1993. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1 IIIB rgp120 subunit vaccine. Lancet 342:69.
6. Gorse, G. J., D. H. Schwartz, B. S. Graham, T. J. Matthews, D. M. Stablein, S. E. Frey, R. B. Belshe, M. L. Clements, P. F. Wright, M. Eibl, and P. E. Fast. 1994. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin. Exp. Immunol. 98:178.
7. Hoth, D. F., D. P. Bolognesi, L. Corey, and S. H. Vermund. 1994. HIV vaccine development: a progress report. Ann. Intern. Med. 8:603.
8. Pincus, S. H., K. G. Messer, P. L. Nara, W. A. Blattner, G. Colclough, and M. Reitz. 1994. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. J. Clin. Invest. 93:2505.
9. Pincus, S. H., K. G. Messer, and S.-L. Hu. 1994. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection. J. Clin. Invest. 93:140.
10. Pincus, S. H., K. G. Messer, D. H. Schwartz, G. K. Lewis, B. S. Graham, W. A. Blattner, and G. Fisher. 1993. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J. Clin. Invest. 91:1987.
11. Prince, A. M., B. Horowitz, L. Baker, R. W. Shulman, H. Ralph, J. Valinsky, A. Cundell, B. Brotman, W. Boehle, F. Rey, M. Piet, H. Reesink, N. Lelie, M. Tersmette, and F. Miedema. 1988. Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV. Proc. Natl. Acad. Sci. USA 85:6944.
12. Kayman, S. C., Z. Wu, K. Revesz, H. Chen, R. Kopelman, and A. Pinter. 1994. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus 1 gp120 by fusion glycoproteins containing isolated gp120 domains. J. Virol. 68:400.
13. Pincus, S. H., K. Wehrly, and B. Chesebro. 1991. Use of a focal infectivity assay for testing susceptibility of HIV to antiviral agents. Biotechniques 10:336.
14. VanCott, T. C., F. R. Bethke, V. R. Polonis, M. K. Gorny, S. Zolla-Pazner, R. R. Redfield, and D. L. Birx. 1994. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J. Immunol. 153:449.
15. VanCott, T. C., L. D. Loomis, R. R. Redfield, and D. L. Birx. 1992. Real-time biospecific interaction analysis of antibody reactivity to peptides from the envelope glycoprotein, gp160, of HIV-1. J. Immunol. Methods 146:163.
16. Pincus, S. H., and K. Wehrly. 1990. AZT demonstrates anti-HIV-1 activity in persistently infected cell lines: implications for combination chemotherapy and immunotherapv. J. Infect. Dis. 162:1233.
17. Pincus, S. H., R. L. Cole, E. M. Hersh, D. Lake, Y. Masuho, P. J. Durda, and J. McClure. 1991. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein. J. Immunol. 146:4315.
18. Pincus, S. H., and J. McClure. 1993. Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 90:332.
19. Young, I. T. 1977. Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J. Histochem. Cytochem. 25:935.
20. Goudsmit, J., C. Debouck, R. H. Meloen, L. Smit, M. Bakker, D. M. Asher, A. V. Wolff, C. J. Gibbs, Jr., and D. C. Gajdusek. 1988. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl. Acad. Sci. USA 85:4478.
21. Javaherian, K., A. J. Langlois, G. J. LaRosa, A. T. Profy, D. P. Bolognesi, W. C. Herlihy, S. D. Putney, and T. J. Matthews. 1990. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 250: 1590.
22. Kennedy, R. C., R. D. Henkel, D. Pauletti, J. S. Allan, T. H. Lee, M. Essex, and G. R. Dreesman. 1986. Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein. Science 231:1556.
23. Dalgleish, A. G., T. C. Chanh, R. C. Kennedy, P. Kanda, P. R. Clapham, and R. A. Weiss. 1988. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology 165:209.
24. Evans, D. J., J. McKeating, J. M. Meredith, K. L. Burke, K. Katrak, A. John, M. Ferguson, P. D. Minor, R. A. Weiss, and J. W. Almond. 1989. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature 339:385.
25. Conley, A. J., J. A. Kessler II, L. J. Boots, J.-S. Tung, B. A. Arnold, P. M. Keller, A. R. Shaw, and E. A. Emini. 1994. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. USA 91:3348.
26. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642.
27. Sun, N.-C., D. D. Ho, C. R. Y. Sun, R. S. Liou, W. Gordon, M. S. C. Fung, X.-L. Li, R. C. Ting, T.-H. Lee, N. T. Chang, and T.-W. Chang. 1989. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency vims type 1 gp120. J. Virol. 63:3579.
28. Lasky, L. A., G. Nakamura, D. H. Smith, C. Fennie, C. Shimasaki, E. Patzer, P. Berman, T. Gregory, and D. J. Capon. 1987. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 50:975.
29. Chesebro, B., and K. Wehrly. 1988. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J. Virol. 62:3779.
30. Graham, B. S., G. J. Gorse, D. H. Schwartz, M. C. Keefer, M. J. McElrath, T. J. Matthews, P. F. Wright, R. B. Belshe, M. L. Clements, R. Dolin, L. Corey, D. P. Bolognesi, D. M. Stablein, J. R. Esterlitz, and S.-L. Hu. 1994. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. J. Infect. Dis. 170:782.
31. Steimer, K. S., C. J. Scandella, P. V. Skiles, and N. L. Haigwood. 1991. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 254:105.
32. VanCott, T. C., F. R. Bethke, D. S. Burke, R. R. Redfield, and D. L. Birx. 1995. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J. Immunol. 155: 4100.
33. Gonczol, E., K. Berensci, S. Pincus, V. Endresz, C. M'eric, E. Paoletti, and S. A. Plotkin. 1995. Preclinical evaluation of an ALVAC (canarypox) human CMV glycoprotein B vaccine candidate. Vaccine 13:1080.
34. Benacerraf, B., and R. N. Germain. 1978. The immune response genes of the major histocompatibility complex. Immunol. Rev. 38:70.
35. Engelhard, V. H. 1994. Structure of peptides associated with class I and class II MHC molecules. Annu. Rev. Immunol. 12:181.
36. Artenstein, A. W., T. C. VanCott, J. R. Mascola, J. K. Carr, P. A. Hegerich. J. Gaywee, E. Sanders-Buell, M. L. Robb, D. E. Dayhoff, and S. Thitivichianlert. 1995. Dual infection with HIV-1 of distinct envelope subtypes in humans. J. Infect. Dis. 171:805.
37. Profy, A. T., P. A. Salinas, L. I. Eckler, N. M. Dunlop, P. L. Nara, and S. D. Puney. 1990. Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual. J. Immunol. 144:4641.
38. Back, N. K. T., C. Thiriart, A. Delers, C. Ramantarsing, C. Bruck, and J. Goudsmit. 1990. Association of antibodies blocking HIV gp120-sCD4 attachment with viral neutralizing activity in human sera. J. Med. Virol. 31:200.
39. Kang, C.-Y., P. L. Nara, S. Chamat, V. Caralli, T. Ryskamp, N. Haigwood, R. Newman, and H. Kohler. 1991. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in HIV-infected humans. Proc. Natl. Acad. Sci. USA 88:6171.
40. Gorny, M. K., J. P. Moore, A. J. Conley, S. Karwowska, J. Sodroski, C. Williams, S. Burda, L. J. Boots, and S. Zolla-Pazner. 1994. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of HIV-1. J. Virol. 68:8312.
41. Moore, J. P., H. Yoshyama, Q. J. Sattentau, M. Thali, S. W. Poon, M. S. Fung, F. Traincard, J. E. Robinson, D. D. Ho, and J. Sodroski. 1993. Probing the structure of the V2 domain of HIV-1 surface glycoprotein gp120 with a panel of monoclonal antibodies. J. Virol. 67:6136.
42. Warrier, S. V., A. Pinter, W. J. Honnen, M. Girard, E. Muchmore, and S. A. Tilley. 1994. A novel, glycan dependent epitope in the V2 domain of HIV-1 gp120 is recognized by a highly potent, neutralizing chimpanzee antibody. J. Virol. 68:4636.
43. Muster, T., R. Guinea, A. Trkola, M. Purtscher, A. Klima, F. Steindl, P. Palese, and H. Katinger. 1994. Cross-neutralizing activity against divergent HIV-1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 68:4031.
44. Chanh, T. C., G. R. Dreesman, P. Kanda, G. P. Linette, J. T. Sparrow, D. D. Ho, and R. C. Kennedy. 1986. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J. 5:3065.
45. Sattentau, Q. J., S. Zolla-Pazner, and P. Poignard. 1995. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 206:713.
46. Pincus, S. H., K. Wehrly, R. Cole, H. Fang, G. K. Lewis, J. McClure, A. J. Conley, B. Wahren, M. R. Posner, A. L. Notkins, S. A. Tilley, A. Pinter, L. Eiden, M. Teintze, and D. Dorward. 1996. In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on the HIV-1 envelope glycoprotein gp160. AIDS Res. Hum. Retroviruses 12:1041.